You are here

  • Home
  • Archive
  • Volume 16, Issue 3
  • Use of antidepressants in the second trimester is associated with reduced pregnancy duration, and third trimester antidepressant use with infant convulsions

Article Text

Article menu
Download PDFPDF
Midwifery
Cohort study
Use of antidepressants in the second trimester is associated with reduced pregnancy duration, and third trimester antidepressant use with infant convulsions
  1. Jennifer L Payne
  1. Department of Psychiatry, Johns Hopkins School of Medicine, Baltimore, Maryland, USA
  1. Correspondence to : Dr Jennifer L Payne
    Department of Psychiatry, Johns Hopkins School of Medicine, 550 N. Broadway, Suite 305, Baltimore, MD 21205, USA; jpayne5{at}jhmi.edu

https://doi.org/10.1136/eb-2012-101002

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Commentary on: Hayes RM, Wu P, Shelton RC, et al. Maternal antidepressant use and adverse outcomes: a cohort study of 228 876 pregnancies. Am J Obstet Gynecol 2012; 207: 49.e1– 9.OpenUrlCrossRefPubMed

    Implications for practice and research

    • Second trimester exposure to antidepressants was associated with preterm birth.

    • Third trimester exposure was associated with infant convulsions.

    • The absolute risk for both outcomes is extremely low and most infants will not have these complications.

    • Decisions about whether to use antidepressants during pregnancy should include the severity of the mother's psychiatric illness.

    • Large studies that include severity of the mother's illness need to be conducted.

    Context

    Approximately 10–20% of women will meet the criteria for major depressive disorder (MDD) during their lifetime, including during pregnancy.1 Rates of antidepressant exposure …

    View Full Text

    Footnotes

    • Competing interests JLP has received expert testimony fees from Astra Zeneca and Pfizer, and has served on an Advisory Board for Pfizer.